BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 20888234)

  • 1. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival.
    Das P; Puri T; Jha P; Pathak P; Joshi N; Suri V; Sharma MC; Sharma BS; Mahapatra AK; Suri A; Sarkar C
    J Clin Neurosci; 2011 Jan; 18(1):66-70. PubMed ID: 20888234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of molecular biomarkers in glioblastoma.
    Ang C; Guiot MC; Ramanakumar AV; Roberge D; Kavan P
    Can J Neurol Sci; 2010 Sep; 37(5):625-30. PubMed ID: 21059509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic implication of alterations in epidermal growth factor receptor and MGMT in glioblastoma].
    Zhang LY; Ge HJ; Wang LM; Zhao LH; Liu L; Zhang DJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):186-191. PubMed ID: 30831643
    [No Abstract]   [Full Text] [Related]  

  • 5. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
    Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL
    J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathology: commonly monitored glioblastoma markers: EFGR, EGFRvIII, PTEN, and MGMT.
    Camara-Quintana JQ; Nitta RT; Li G
    Neurosurg Clin N Am; 2012 Apr; 23(2):237-46, viii. PubMed ID: 22440867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
    Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T
    Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
    Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
    Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
    Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].
    Kamoshima Y; Motegi H; Terasaka S; Kobayashi H; Yamaguchi S; Murata J; Tanaka S; Houkin K
    No Shinkei Geka; 2012 Feb; 40(2):129-35. PubMed ID: 22281465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma.
    Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH
    Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.
    Richard S; Tachon G; Milin S; Wager M; Karayan-Tapon L
    Cancer Med; 2020 Sep; 9(17):6344-6353. PubMed ID: 32666673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Characteristics of Thalamic Gliomas in Adults.
    Wang T; Niu X; Gao T; Zheng L; Qiu Y; Mao Q
    J Mol Neurosci; 2021 Aug; 71(8):1598-1604. PubMed ID: 33523385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma.
    Uno M; Oba-Shinjo SM; Camargo AA; Moura RP; Aguiar PH; Cabrera HN; Begnami M; Rosemberg S; Teixeira MJ; Marie SK
    Clinics (Sao Paulo); 2011; 66(10):1747-55. PubMed ID: 22012047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S; Rui Q; Wang Y; Heo HY; Zou T; Yu H; Zhang Y; Wang X; Du Y; Wen X; Chen F; Wang J; Eberhart CG; Zhou J; Wen Z
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
    Huang L; Jiang T; Yuan F; Li GL; Cui Y; Liu EZ; Wang ZC
    Neuropathol Appl Neurobiol; 2009 Aug; 35(4):367-379. PubMed ID: 19019173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.